^
CANCER:

Malignant Pleural Mesothelioma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
cisplatin + pemetrexed
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
pemetrexed
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
carboplatin + pemetrexed
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
nivolumab
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
bevacizumab
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
pembrolizumab
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
carboplatin + raltitrexed
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
GC
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
gemcitabine
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
vinorelbine tartrate
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
ramucirumab
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
cisplatin
Sensitive
:
A2
No biomarker
Malignant Pleural Mesothelioma
carboplatin
Sensitive
:
A2
NF2 deletion
Malignant Pleural Mesothelioma
IK-930
Sensitive
:
B
PD-L1 expression
Malignant Pleural Mesothelioma
nivolumab
Sensitive
:
C1
WT1 expression
Malignant Pleural Mesothelioma
nivolumab + galinpepimut-S
Sensitive
:
C3
TMB-L
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant
:
C3
TMB-L
Malignant Pleural Mesothelioma
PD-L1 inhibitor
Resistant
:
C3
PD-L1 underexpression
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant
:
C3
ERCC1 expression
Malignant Pleural Mesothelioma
GC
Sensitive
:
C3
RRM1 expression
Malignant Pleural Mesothelioma
GC
Sensitive
:
C3
MSLN overexpression
Malignant Pleural Mesothelioma
TC-210
Sensitive
:
C3
ASS1 mutation
Malignant Pleural Mesothelioma
cisplatin + pemetrexed + pegargiminase
Sensitive
:
C3
BAP1 deletion
Malignant Pleural Mesothelioma
pemetrexed
Sensitive
:
C3
PD-L1 overexpression
Malignant Pleural Mesothelioma
nivolumab
Sensitive
:
C4
EML4-ALK I1171N + EML4-ALK L1196M
Malignant Pleural Mesothelioma
alectinib
Resistant
:
C4
CD74-ROS1 fusion
Malignant Pleural Mesothelioma
crizotinib
Sensitive
:
C4